{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
metyrapone
to a specific field?
There is one exact (name or code) match for metyrapone
Status:
US Approved Rx
(1961)
Source:
NDA012911
(1961)
Source URL:
First approved in 1961
Source:
NDA012911
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Metyrapone (trade name Metopirone) is a drug used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism). Metopirone, metyrapone USP, is an inhibitor of endogenous adrenal corticosteroid synthesis, available
as 250-mg capsules for oral administration. The pharmacological effect of Metopirone is to reduce cortisol and corticosterone production by
inhibiting the 11-β-hydroxylation reaction in the adrenal cortex. Removal of the strong inhibitory
feedback mechanism exerted by cortisol results in an increase in adrenocorticotropic hormone (ACTH)
production by the pituitary. With continued blockade of the enzymatic steps leading to production of
cortisol and corticosterone, there is a marked increase in adrenocortical secretion of their immediate
precursors, 11-desoxycortisol and desoxycorticosterone, which are weak suppressors of ACTH release,
and a corresponding elevation of these steroids in the plasma and of their metabolites in the urine.
These metabolites are readily determined by measuring urinary 17-hydroxycorticosteroids (17-OHCS)
or 17-ketogenic steroids (17-KGS). Because of these actions, Metopirone is used as a diagnostic test, with urinary 17-OHCS measured as an
index of pituitary ACTH responsiveness. Metopirone may also suppress biosynthesis of aldosterone,
resulting in a mild natriuresis.
Showing 1 - 3 of 3 results
Status:
US Approved Rx
(1961)
Source:
NDA012911
(1961)
Source URL:
First approved in 1961
Source:
NDA012911
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Metyrapone (trade name Metopirone) is a drug used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism). Metopirone, metyrapone USP, is an inhibitor of endogenous adrenal corticosteroid synthesis, available
as 250-mg capsules for oral administration. The pharmacological effect of Metopirone is to reduce cortisol and corticosterone production by
inhibiting the 11-β-hydroxylation reaction in the adrenal cortex. Removal of the strong inhibitory
feedback mechanism exerted by cortisol results in an increase in adrenocorticotropic hormone (ACTH)
production by the pituitary. With continued blockade of the enzymatic steps leading to production of
cortisol and corticosterone, there is a marked increase in adrenocortical secretion of their immediate
precursors, 11-desoxycortisol and desoxycorticosterone, which are weak suppressors of ACTH release,
and a corresponding elevation of these steroids in the plasma and of their metabolites in the urine.
These metabolites are readily determined by measuring urinary 17-hydroxycorticosteroids (17-OHCS)
or 17-ketogenic steroids (17-KGS). Because of these actions, Metopirone is used as a diagnostic test, with urinary 17-OHCS measured as an
index of pituitary ACTH responsiveness. Metopirone may also suppress biosynthesis of aldosterone,
resulting in a mild natriuresis.
Status:
US Approved OTC
Source:
21 CFR 331.11(m) antacid:tartrate-containing tartrate (acid or salt)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Tartaric acid is found in many plants such as grapes, tamarinds, pineapples, mulberries and so on. Wine lees (called mud in the US), the sediment collected during the fermentation of grapes, contains potassium bitartrate (potassium hydrogen tartrate) as its major component. L-(+)-tartaric acid is an enantiomer of tartaric acid. Twenty five years before the tetrahedral structure for carbon was proposed in 1874 to explain the optical activity and other properties of organic compounds, Louis Pasteur discovered the existence of enantiomerism in tartaric acid. L-(+)-tartaric acid is widely used in food and beverage as acidity regulator with E number E334.
Status:
US Approved Rx
(1961)
Source:
NDA012911
(1961)
Source URL:
First approved in 1961
Source:
NDA012911
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Metyrapone (trade name Metopirone) is a drug used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism). Metopirone, metyrapone USP, is an inhibitor of endogenous adrenal corticosteroid synthesis, available
as 250-mg capsules for oral administration. The pharmacological effect of Metopirone is to reduce cortisol and corticosterone production by
inhibiting the 11-β-hydroxylation reaction in the adrenal cortex. Removal of the strong inhibitory
feedback mechanism exerted by cortisol results in an increase in adrenocorticotropic hormone (ACTH)
production by the pituitary. With continued blockade of the enzymatic steps leading to production of
cortisol and corticosterone, there is a marked increase in adrenocortical secretion of their immediate
precursors, 11-desoxycortisol and desoxycorticosterone, which are weak suppressors of ACTH release,
and a corresponding elevation of these steroids in the plasma and of their metabolites in the urine.
These metabolites are readily determined by measuring urinary 17-hydroxycorticosteroids (17-OHCS)
or 17-ketogenic steroids (17-KGS). Because of these actions, Metopirone is used as a diagnostic test, with urinary 17-OHCS measured as an
index of pituitary ACTH responsiveness. Metopirone may also suppress biosynthesis of aldosterone,
resulting in a mild natriuresis.
